Real-world study of EGFR-targeted therapy after surgery for early lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well a third-generation EGFR-targeted pill works after surgery for patients with stage IA non-small cell lung cancer that has certain high-risk features and an EGFR mutation. The goal is to see if this treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stage IA non-small cell lung cancer (a type of lung cancer) with high-risk features
- Your tumor has an EGFR mutation (a specific change in the cancer cells)
- You have not had any previous cancer treatment for this lung cancer
- You have had surgery to remove the cancer, or are planning to have surgery
- You are planning to take or have already started taking a third-generation EGFR-targeted pill (like osimertinib) after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This phase 3 trial tests adding toripalimab (an immunotherapy) to standard chemotherapy after surgery for certain stage II to IIIB (N2) lung cancers. It aims to lower the chance the cancer comes back by treating tiny remaining cancer cells and supporting your immune system.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.